|
Advisory
Committees
Nature and Basis Statements of Conflict(s)
of Interest for Voting Members of FDA Advisory Committee Members
The Agency is revising its procedures
regarding the disclosure of conflicts of interest and waivers for
voting advisory committee members in order to implement the requirements
of section 795 of Pub. L. No. 109-97 (Agriculture, Rural Development,
Food and Drug Administration, and Related Agencies Appropriations
Act, 2006) (Nov. 10, 2005). This information is being provided as
an interim measure to comply with the requirements of this law.
Cellular, Tissue and Gene Therapies Advisory Committee
March 29-30, 2007
Glenn Dranoff, M.D.
- 18 U.S.C. 208 waiver (pdf)
Mary M. Horowitz, M.D.
- 18 U.S.C. 208 waiver (pdf)
Maha Hussian, M.D., FACP
- 18 U.S.C. 208 waiver (pdf)
Mary J. Laughlin, M.D.
- 18 U.S.C. 208 waiver (pdf)
James J. Mule, Ph.D.
- 18 U.S.C. 208 waiver (pdf)
Derek Raghavan, M.D., Ph.D. (Dr. Raghavan was unable to attend this meeting)
- 18 U.S.C. 208 waiver (pdf)
Howard I. Scher, M.D.
- 18 U.S.C. 208 waiver (pdf)
Savio L. C. Woo, Ph.D.
- 18 U.S.C. 208 waiver (pdf)
Page updated:
March 28, 2007
|
|